PowderJect

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

Retrieved on:

Friday, January 6, 2023

James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.

Key Points:

James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.
He is currently Chairman at Orexo AB, Sutura Therapeutics and Celleron Therapeutics and non-executive director of Nasdaq listed company Lava Therapeutics N.V.
Douglas Thomson, CEO of Pneumagen, commented, "We are very pleased to welcome James to the Board who brings a wealth of strategic, corporate and financial expertise to Pneumagen.
James Noble added "I am honoured to take on the role as Chairman of the Board of Directors at Pneumagen, a company that has already delivered highly encouraging early clinical data.

Retrieved on:

Friday, January 6, 2023

James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.

Key Points:

James brings over 30 years of industry experience to the Board from both public and private biotech and healthcare companies.
He is currently Chairman at Orexo AB, Sutura Therapeutics and Celleron Therapeutics and non-executive director of Nasdaq listed company Lava Therapeutics N.V.
Douglas Thomson, CEO of Pneumagen, commented, "We are very pleased to welcome James to the Board who brings a wealth of strategic, corporate and financial expertise to Pneumagen.
James Noble added "I am honoured to take on the role as Chairman of the Board of Directors at Pneumagen, a company that has already delivered highly encouraging early clinical data.